Owonikoko, T. K., Papadopoulos, K. P., Johnson, M. L., Martin, M. G., Moreno, V., Salama, A. K., … Babiker, H. M. (2018). Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. In ANNALS OF ONCOLOGY (Vol. 29, pp. 25–25).

Owonikoko, T. K., K. P. Papadopoulos, M. L. Johnson, M Gil Martin, V. Moreno, A. K. Salama, E. Calvo, et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.” In ANNALS OF ONCOLOGY, 29:25–25, 2018.

Owonikoko TK, Papadopoulos KP, Johnson ML, Martin MG, Moreno V, Salama AK, et al. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. In: ANNALS OF ONCOLOGY. 2018. p. 25–25.

Owonikoko, T. K., et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.” ANNALS OF ONCOLOGY, vol. 29, 2018, pp. 25–25.

Owonikoko TK, Papadopoulos KP, Johnson ML, Martin MG, Moreno V, Salama AK, Calvo E, Yee NS, Safran H, Aljumaily R, Mahadevan D, Niu J, Mohan KK, Li J, Stankevich E, Mathias M, Lowy I, Fury MG, Babiker HM. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. ANNALS OF ONCOLOGY. 2018. p. 25–25.